1Assistant Professor, Dr. B. Lal Institute of Biotechnology, Jaipur, University of Rajasthan, Rajasthan, India
2Student, Dr. B. Lal Institute of Biotechnology, Jaipur, University of Rajasthan, Rajasthan, India
3Alexander von Humboldt Fellow (Germany) Professor (Retd.), Department of Botany, University of Rajasthan, Jaipur, University of Rajasthan, Rajasthan, India
*(Corresponding author) email id: aditinag1@gmail.com
The SARS-CoV-2 emergence, causing the global pandemic, triggered researchers worldwide to develop the safest vaccine at the earliest. Previous studies have portrayed a high degree of similarity between the SARS-CoV (2002-03 outbreak) and SARS-CoV-2 (2019-till present). Till 22 December, a total of 233 vaccines development projects are being executed, of which majority are in pre-clinical phase and few in clinical stages. Of all vaccine development programs, various subunit, protein vector & DNA vaccines candidates were efficacious in pre-clinical studies but only few reached the clinical trials. The most developed vaccines so far to reach out to the public (UK) are PFIZER (BioNTech), Moderna, AstraZeneca and R-Pharm Germany GmbH vaccines. This review aims to collate all the vaccine candidate approaches towards this deadly virus and try to discuss a few concerns and challenges currently posed to the worldwide vaccination drive.
Covid19, SARS-CoV-2, Astra Zeneca, Respiratory Syndrome virus, Symptoms
